Actualités

HTC research brief: Akkermansia MucT and the 2026 weight-regain trial

1:19 am 20 August 2026 0 Comments

This brief is shared with patients of Health Therapies Clinics and with the practitioners who hire rooms in our clinics.

The announcement

On 19 August 2026 Metagenics released an ingredient feature on Akkermansia muciniphila MucT, a pasteurised gut bacterium it calls a next-generation postbiotic. The feature centres on Mount and colleagues, Nature Medicine 2026: a randomised controlled trial of 84 adults with overweight or obesity who, after an eight-week weight-loss phase, took MucT or placebo daily for 24 weeks, with weight regain as the outcome. Metagenics also promoted a video with Professor Willem de Vos, whose team first described the bacterium, through its practitioner login. MucT is sold in UltraFlora Weight & Metabolic Health with Akkermansia.

How HTC handles it

Practitioner education material and ordering links in the newsletter are for practitioners only and are not offers to the public. For patients, the message is simple: no product is suggested by this brief. Suitability is decided by a practitioner at a consultation, with attention to medicines and medical care. Metagenics products are sold to patients through the group's Healthy Market.

Patients can ask about this at their next consultation. Bookings: 0410 699 065.

Comments are disabled

Search
Archives
Recent entries
Categories